The Med­i­cines Com­pa­ny touts fresh ev­i­dence that their PC­SK9si can durably bat down LDL

The ex­ec­u­tive crew at The Med­i­cines Com­pa­ny say that they re­main on track with an ear­ly-stage PC­SK9 that re­li­ably knocked down lev­els of bad cho­les­terol, clear­ing one more hur­dle in a long jour­ney aimed at de­liv­er­ing a new ther­a­py that can beat out the pi­o­neers in the field with a drug that will on­ly need to be ad­min­is­tered two, three or four times a year.

There’s noth­ing new about PC­SK9 drugs, de­signed to slash LDL. Am­gen and the Re­gen­eron/Sanofi team de­liv­ered back-to-back ther­a­pies that do the same thing. But The Med­i­cines Com­pa­ny be­lieves it can roll up the mar­ket with a new and bet­ter ap­proach in-li­censed from Al­ny­lam that will be much eas­i­er to re­main com­pli­ant on.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA